ミトコンドリア機能障害とアポトーシスは,アルファ-B-クリスタリン・デスミンに関連した心筋疾患における病原性プロセスの基礎となっている
Alina Maloyan1, Atsushi Sanbe, Hanna Osinska
1Division of Molecular Cardiovascular Biology, Cincinnati Children's Hospital, Cincinnati, Ohio, USA.
Circulation
|December 1, 2005
まとめ
ミュータントアルファ-B-クリスタリン (CryAB) は,ミトコンドリア・サルコメア構造を乱すことで,デズミン関連心筋病を引き起こす. これは,ミトコンドリア機能障害とアポトーシスによる心不全につながる.
科学分野:
- 心血管生物学 心血管生物学
- ミトコンドリア生物学
- プロテイン病症は,タンパク質の欠乏症である.
背景:
- ミトコンドリアとサルコメアは,細胞骨格に依存する重要な建築的関係を維持しています.
- アルファ-B-結晶 (CryAB) の特定の変異 (R120G) は,CryABとdesminのアミロイド陽性集合体によって特徴づけられる,デスミン関連心筋病を引き起こす.
- この疾患は,CryAB.変異体の心臓特異的発現を介してマウスでモデル化することができます.
研究 の 目的:
- R120GのCryAB発現が心筋細胞の構造と機能に及ぼす直接的な影響を調査する.
- デスミン関連心筋疾患における心不全につながる一連の出来事を解明する.
主な方法:
- R120G CryAB.でアデノウイルス媒介による成人心筋細胞のトランスフェクションを用いたインビトロ研究.
- R120G CryAB.の心臓特異的発現を有するトランスジェニックマウスにおけるインビボ試験.
- 収縮力学,細胞骨格の整合性,ミトコンドリアの組織,酸素消費,アポプトシス経路の評価.
主要な成果:
- In vitroでは,R120Gの発現により,心筋細胞の収縮メカニズムが変化した.
- In vivoでは,早期の細胞骨格障害が臓器機能不全に先行し,ミトコンドリアの構造の変化が観察されました.
- ミトコンドリア機能不全には,複合体I連結呼吸の減少,透性トランジションの毛穴の変化,内膜の潜在力の低下,それに続くアポトーシスと心不全が含まれていた.
結論:
- R120G CryABによって例示される心臓のチャペロン機能障害は,心筋細胞のメカニズムとミトコンドリア・サルコメア構造を急激に損なう.
- これらの干渉は,ミトコンドリア機能障害,アポトーシスの活性化,そして最終的には心不全を引き起こす.
関連する概念動画
01:26Cross-bridge Cycle
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...